[<sup>18</sup>F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma following<i>BRAF</i>-Targeted Therapy
Preoperative FDG-PET noninvasively identifies lesions with residual high-risk pathologies following neoadjuvant <i>BRAF</i>-directed targeted therapy and immunotherapy for <i>BRAF</i>-mutated ATC. FDG-PET avidity may serve as an early prognostic marker that correlates with residual high-risk pathology in <i>BRAF</i>-mutated ATC after neoadjuvant therapy.
Authors
- Priyanka Chandrasekhar Iyer (ORCID: https://orcid.org/0000-0003-4863-5585)
- Mark Zafereo (ORCID: https://orcid.org/0000-0001-7918-9739)
- Xiao Zhao (ORCID: https://orcid.org/0000-0003-2485-9445)
- Naifa Lamki Busaidy (ORCID: https://orcid.org/0000-0002-3808-6378)
- Jennifer Wang (ORCID: https://orcid.org/0000-0002-0807-3832)
- Anastasios Maniakas (ORCID: https://orcid.org/0000-0002-4354-2841)
- Alexander Khalaf (ORCID: https://orcid.org/0000-0001-6366-6318)
- Kim O. Learned (ORCID: https://orcid.org/0000-0002-5125-4022)
- Samir A. Dagher (ORCID: https://orcid.org/0000-0003-0155-7444)
- S. Mohsen Hosseini (ORCID: https://orcid.org/0000-0003-3626-9928)
- Ramona Dadu (ORCID: https://orcid.org/0000-0002-3776-208X)
- Richard Dagher (ORCID: https://orcid.org/0009-0001-7666-2989)
- Maria E. Cabanillas (ORCID: https://orcid.org/0000-0002-5124-1811)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- American Journal of Neuroradiology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.3174/ajnr.a8588
- Citations
- 2
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.72